Annual Report 2001 - The Hospital for Sick Children

Home chemotherapy for children
with cancer. Stevens B, Greenberg M (coinvestigators):
HSC Foundation ,
HealthCanada ($280,771 1998 - 2001).
hSNF5/INI1 in childhood leukemia.
Malkin D, Teshima I: Leukemia Research Fund
of Canada ($96,000 2000 - 2002).
Impact of Chelation on iron
transport and regulations. Templeton
D, Olivieri NF: Medical Research Council of
Canada MT-11270 ($240,000 1999 - 2004).
In vitro activity of squalene as a
chemopotentiating agent in
neuroblastoma cell lines and as a
cytoprotective agent in bone
marrow progenitors. Baruchel S, Das B:
Issho Genki International Limited
($88,050 2000 - 2002).
Incidence of Heparin Induced
Thrombocytopenia (HIT) in Pediatric
Patients: A Prospective Cohort
Study. Carcao M, Blanchette V, Rand M, Cox P,
Parshuram C, Leaker M: Hospital for Sick
Children Seed Grant ($8,670 2000 - 2002).
Induction of Anti-Leukemic Cellular
Immunity. Saunders EF, Narendran A:
Research Institute, The Hospital for Sick
Children ($31,580 2001 - 2003).
Interdisciplinary Health Research
Team (IHRT) in Musculoskeletal
Neoplasia. Bell RL, Andrulis I, Wunder J,
Alman B, Malkin D, Davies A, Greenberg ML, Bull
S, O'Sullivan B, Kandel R, Bramwell V, Hill R:
Canadian Institutes for Health Research
($7,140,000 2001 - 2006).
Investigations of recipient immunity
against allogenic leukoreduced
platelet transfusions. Semple JW,
Freedman J, Blanchette V (Co-Investigator): Canadian
Blood Services Research and Development
Program ($242,779 1999 - 2002).
Magnetic resonance imaging studies
of severe haemophilia A patients on
a randomized trial comparing two
regimens of recombinant factor VIII
prophylaxis. Carcao, MD, Blanchette V (Co-
Principal Investigator), Feldman BM, Babyn P:
Bayer Canada ($140,183 2001 - 2003).
Minimal residual disease in the
stem cell collections (pre and post
CD34 selection) of patients with
30
neuroblastoma that have
undergone high-dose therapy with
peripheral blood stem cell rescue.
Doyle J, Zielenska M, Thorner P, Sharathkumar A:
AMGEN ($5,000 2001 - 2002).
Molecular determinants of tumor
formation in Li-Fraumeni syndrome.
Malkin D: National Cancer Institute of
Canada ($336,000 2001 - 2004).
Multidrug resistance P170 and MRP
proteins in failure of pediatric
cancer therapy. Chan HSL, Ling V, Cole S,
Deeley R, Grogan TM, Sehested M, DeBoer G,
Scheper RJ, Ikegaki N, Gallie BL: NCIC Research
Grant ($295,224 1999 – 2002).
National Pediatric Cancer Pilot
Study. Ross J, Buckley JD, Robison LL, Pollock B,
Deapen D, Bhatia S, Malkin D, Hudson M, Krailo
M, Khayat A: National Institutes of Health
($417,964 2000 - 2002).
Neuro-Oncology Education
materials for Families. P. McGee, S.
Awery, S. Baruchel, E. Bouffet, D. Brownstone, P.
Dirks, N. Laperriere, T. Popov, B. Spiegler, C. Van
Halderen: Centre for Health Information
and Promotion, Hospital for Sick
Children, Toronto ($30,000 2001).
Non-transferring-bound plasma
iron and deferoxamine therapy.
Porter J, Olivieri NF: National Institutes of
Health - HL-97-013 (US Funds)
($1,305,480 1998 - 2003).
Pain in child health: An innovative,
transdisciplinary, cross-Canada
research training consortium.
McGrath PJ, Barr R, Baruchel S, Brown S, Camfield
C, Chambers C, Connolly J, Craig K, Dube L,
Feldman B, Finley G, Frager G, Gibbins S, Grunau
R, Harman K, Hetherington C, Howlett A, Johnston
C, Kenny N, Koren G, Langer J, Murray M,
Oberlander T, Ohlsson A, Otley A, Rathwell T, Salter
M, Schellinck H, Stevens B, Taddio A, Unruh A, Von
Baeyer C, Walker C: Canadian Institutes of
Health Research ($1,800,000 2002 - 2008).
Pharmacokinetics of Kogenate(R).
Carcao MD, Blanchette V (Co-Principal Investigator),
Lillicrap D: Bayer Canada ($85,505 2001).
Phase I trial of Temodal using an
extended continuous oral schedule
in recurrent pediatric brain tumors.
Baruchel S: Schering-Plough Canada
($90,000 1999 - 2002).
Pilot Study of Combination Therapy
of Temozolomide and Radiation
Therapy in brainstem glioma. S.
Baruchel, E. Bouffet, N. Tariq, D. Hargrave:
B.R.A.I.N. Child ($44,980 2001).
Pilot study of low dose
chemotherapy and cyclo-oxygenase-
2 inhibitor as anti-angiogenic
therapy in children with
progressive or recurrent solid
tumors. Baruchel S: Pharmacia
Corporation ($358,215 2001 - 2004).
Pilot study of low dose
Temozolomide and radiation in
brain stem glioma. Baruchel S:
BrainChild and Schering-Plough Canada
($32,000 2002 - 2004).
Prevention of platelet
alloimmunization in a human-PBL-
SCID mouse model. Lazarus A, Freedman J,
Blanchette (Co-Investigator): Canadian Blood
Services Research and Development
Program ($286,912 1999 - 2002).
Psychological Outcomes and Quality
of Life after Pediatric Bone Marrow
Transplantation. Saunders EF, Barrera M:
National Cancer Institute of Canada
($240,000 2000 - 2003).
Studies to determine the presence
of SV40 viral sequences and anti-
SV40 antibodies in patients with
osteosarcoma. Malkin D: Pediatric Oncology
Group of Ontario ($41,300 2000 - 2001).
The relationship between
parvovirus B19 infectionn and
prolonged febrile neutropenia in
children undergoing cancer
chemotherapy. Grant R., Sung L., Tellier R.,
Petric, M., Allen U., A, Matlow A, Feldman B:
Paediatric Consultants Research Grants ,
Hospital for Sick Children ($4,968 2002).
Validity of a modified standard
gamble technique to measure
quality of life in children with
significant medical conditions.
Feldman BM, Sung L, Ingber S, Young NL,
Blanchette V, Greenberg ML, Doyle JJ: Pediatric
Consultants ($4,988 2001 - 2002).
Various apoptosis pathways in SDS.
Yigal Dror: Shwachman-Diamond Canada
($79,000 2001 - 2003).